



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



European Network of Centres
for Pharmacoepidemiology and Pharmacovigilance

Report from the Steering Group

ENCePP Plenary Meeting, 22 November 2016

Presented by Susana Perez-Gutthann
Deputy Chair, ENCePP Steering Group



An agency of the European Union





Key points

- Looking back: key achievements since last plenary meeting
- The EU PAS Register
- Looking ahead to 2017 and beyond
- Personal reflections

ENCePP Working Groups

- WG 1 (Research Standards and Guidances)

Chair: Alejandro Arana

- e.g. Revision 5 of ENCePP Guide on Methodological Standards in Pharmacoepidemiology; Revision 3 of ENCePP Checklist for Study Protocols; end user survey of ENCePP Methods Guide
- Update from meeting on 21 November 2016

No immediate ongoing business in 2016 (but with deliverables in new work plan):

- WG2 (Independence and Transparency)
- WG3 (Data sources and multi-source studies)
- Joint Enpr-EMA - ENCePP working group on paediatric pharmacovigilance



ENCePP Special Interest Groups

- ENCePP Special Interest Group 'Drug research in pregnancy'
Chair: Laura Yates
 - e.g. review of the "Overview of data sources for drug safety in pregnancy research"
 - Update from coordinator meeting 21 November 2016

- ENCePP Special Interest Group 'Measuring the Impact of Pharmacovigilance Activities'
Chair: Agnes Kant
 - Adoption of mandate and work plan
 - Update from coordinator meeting 21 November 2016

The EU PAS Register – Upgrade July 2016

- Performance enhancements:
 - Larger size limit for file uploads; confirmation email for draft entries
- New format of the unique EU PAS reference number: e.g. EUPAS123456
- Static hyperlink to study record
- New data field: 'RMP study category' (mandatory, searchable)
 - EU RMP category 1; EU RMP category 2; EU RMP category 3 (required); Non-EU RMP only; Not applicable
- New data field: 'Other study registration identification number(s)' (free text, searchable)

NEW compliance monitoring measures: more under agenda item 7.4.

The EU PAS Register – some statistics






	Total as of 11/11/2014	Total as of 17/11/2015	Total as of 14/11/2016
Studies registered by ENCePP partners	149	253	349
<i>- Of which sponsored by industry</i>	98	183	264
Studies registered by others	259	413	579
Total studies	408	666	928
ENCePP Seal Studies	27	36	41



The EU PAS Register

(as of 14/11/2016)





Looking ahead: ENCePP Work Plan 2017-2019

October
2016


- SG agreement on draft work plan

November
2016

- Presentation of objectives and deliverables to Plenary

December
2016

- SG adoption of new work plan
- Publication on ENCePP website





Objective

Deliverables

ENCePP delivering to the lifecycle of medicines

- ENCePP input to regulatory decision-making throughout the product lifecycle.

Develop methods for modelling health outcomes of pharmacovigilance activities for impact measurement

- Review of studies on risk minimisation effectiveness to determine health impact of pharmacovigilance activities, including selected examples from scientific literature.
- Recommendations on methods of measuring effectiveness of pharmacovigilance activities.



Objective

Deliverables

Support capacity for pregnancy surveillance

- Recommendations for strategy on pregnancy research, including funding.

Explore additional models for good governance of PhEpi research

- Third party funding mechanism for PAS.
- Strengthen the Code with additional tools to support good governance of pharmacoepidemiological research.



Objective

Address methodological aspects of the generation of evidence-based information supporting the needs of regulatory and HTA decision-making

Optimise functionality and utility of the ENCePP resources database and EU PAS Register

Deliverables

- Gap analysis of guidance in relation to efficacy and effectiveness (PAES guideline).
- Revision of ENCePP Guides on Methodological Standards in Pharmacoepidemiology and ENCePP Checklist for Study Protocols.
- If needed, revision of *Guidelines for good database selection and use in pharmacoepidemiology research*, in collaboration with ISPE.
- Input to EMA guidance on special populations, including paediatrics and pregnancy.

- Improved functionality of the ENCePP resources database and EU PAS Register.
- Increase study registration and status of the EU PAS Register.
- Increase routine surveillance of registrations and compliance follow-up.



Objective

Implement ENCePP
Communications Plan

Deliverables

- Evaluation of achievements of 10 years of ENCePP (2007 to 2017).
- Strengthen tools of communication with ENCePP partners



10th Anniversary ENCePP – Paper on the evolution of pharmacoepidemiology in Europe

Your insights about this 10 years of pharmacoepidemiology in Europe

- What was the best development/achievement/success
- What is the major challenge/area of improvement





Thank you for your attention

- Further information:

www.encepp.eu

encepp_secretariat@ema.europa.eu

- Mark your calendar:

16th ENCePP Plenary meeting, 21 November 2017

